Yazar "Iclek, Sumeyye Koc" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Does Rocuroinum Dose Adjusted Due to Lean Body Weight Provide Adequate Intubation Conditions?: A Prospective Observational Study
    (Wiley-Hindawi, 2022) Demiroz, Duygu; Colak, Yusuf Ziya; Iclek, Sumeyye Koc; Erdogan, Mehmet Ali; Yagci, Neslihan Altunkaya; Durmus, Mahmut; Gulhas, Nurcin
    Introduction and Aim. There is no consensus on the weight parameters to use when titrating the dosage of the neuromuscular blocking agents during intubation. In our study, we administered rocuronium, based on either the lean body weight (LBW) or the total body weight in patients with body mass index (BMI) of 18.5 to 34.9 and compared the duration of action of the drug and its effects on tracheal intubation conditions and hemodynamic parameters. Methods. This is a prospective, observational study. Patients between the ages of 18 and 65 with BMI of 18.5-34.9, who are expected to be under general anesthesia for less than 6 hours, were divided into 3 groups according to their BMI (Group 1 BMI = 18.5-24.9, Group 2 BMI = 25-29.9, Group 3 BMI = 30-34.9). These groups were randomly divided into 2 subgroups: Groups LBW; 1 LBW, 2 LBW, and 3 LBW were given rocuronium intubation dosages based on their LBW while control groups; 1K, 2K, and 3K were given 0.6 mg/kg rocuronium according to their total body weight. The data on the duration of action of rocuronium and its effects on the endotracheal intubation conditions were evaluated. Results. In Group 1, T1 time was found to be significantly longer (p=0.001). Intubation score and the use of additional rocuronium dose were found to be significantly higher in Group 1 LBW than in Group 1K (p=0.001). In Group 1, an additional rocuronium dose was needed to achieve optimal intubation conditions for subgroup 1 LBW. Rocuronium duration of action was found to be significantly longer in control groups 2 and 3, that received TBW-based dosage. Conclusion. In adult patients with a BMI of 18.5 and 24.9 BMI, we report optimal intubation conditions with the LBW-adjusted rocuronium dosage.
  • Küçük Resim Yok
    Öğe
    The Effect of Rocuronium Dosage on Intubation Conditions in Liver Transplant Recipients
    (Galenos Publ House, 2025) Iclek, Sumeyye Koc; Demiroz, Duygu; Colak, Yusuf Ziya; Yagci, Neslihan Altunkaya; Ozdes, Oya Olcay; Erdogan, Mehmet Ali; Gulhas, Nurcin
    Introduction: Neuromuscular blockers (NMB) play an important role in improving conditions in orthotopic liver transplantation (OLT). Depending on clinical conditions, diseases, and pharmacological interactions, the effective NMB dose for complete NMB varies. Our study investigated the effects of rocuronium used during rapid sequence intubation. The effects of this drug on onset of action and intubation conditions were studied in a control group and in an OLT patient group. Methods: The study is prospective, involving 90 patients over the age of 18. The 45 patients scheduled to undergo OLT were assigned to Group 1, while the 45 patients without liver dysfunction scheduled to undergo a 4-6-hour surgery under general anesthesia were assigned to Group 2. Groups were dosed with 1.2 mg/kg rocuronium based on ideal body weight, and the effect on the time to reach a train-of-four (TOF) value of zero (TOF 0), time to intubation scores, and hemodynamic parameters was evaluated. Results: The demographic data across the groups were comparable. No significant differences were observed between the groups concerning TOF 0 time (p=0.806), intubation times (p=0.987), and intubation scores (p=0.898). However, when evaluating OLT patients individually, a statistically significant correlation was found between TOF 0 time and Child score (p=0.029, p<0.05). Conclusion: In patients with end-stage liver disease undergoing OLT, administering rocuronium at a dosage of 1.2 mg/kg based on ideal body weight, during rapid sequence intubation results in sufficient intubation conditions. Furthermore, there were no delays noted in the onset of rocuronium's action.